---
title: "EIR Biopharma Announces IPO Of 3.8 Mln Shares"
description: "EIR BIOPHARMA INC - ANNOUNCES IPO OF 3,750,000 SHARES - SEC FILINGEIR BIOPHARMA INC - IPO PRICE ESTIMATED BETWEEN $4.00 AND $5.00 PER SHARE - SEC FILINGEIR BIOPHARMA INC - INTENDS TO LIST ON NYSE - SE"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276174808.md"
published_at: "2026-02-17T21:57:41.000Z"
---

# EIR Biopharma Announces IPO Of 3.8 Mln Shares

> EIR BIOPHARMA INC - ANNOUNCES IPO OF 3,750,000 SHARES - SEC FILINGEIR BIOPHARMA INC - IPO PRICE ESTIMATED BETWEEN $4.00 AND $5.00 PER SHARE - SEC FILINGEIR BIOPHARMA INC - INTENDS TO LIST ON NYSE - SEC FILINGEIR BIOPHARMA INC - KINGSWOOD CAPITAL PARTNERS, LLC IS UNDERWRITERS TO IPO- SEC FILING

-   EIR BIOPHARMA INC - ANNOUNCES IPO OF 3,750,000 SHARES - SEC FILING
    
-   EIR BIOPHARMA INC - IPO PRICE ESTIMATED BETWEEN $4.00 AND $5.00 PER SHARE - SEC FILING
    
-   EIR BIOPHARMA INC - INTENDS TO LIST ON NYSE - SEC FILING
    
-   EIR BIOPHARMA INC - KINGSWOOD CAPITAL PARTNERS, LLC IS UNDERWRITERS TO IPO- SEC FILING

### Related Stocks

- [EIGRQ.US - EIGER BIOPHARMACEUTICALS INC](https://longbridge.com/en/quote/EIGRQ.US.md)
- [IRMD.US - iRadimed](https://longbridge.com/en/quote/IRMD.US.md)
- [000863.CN - CS精准医](https://longbridge.com/en/quote/000863.CN.md)
- [GME.DE - Geratherm Medical AG](https://longbridge.com/en/quote/GME.DE.md)
- [562050.CN - Hwabao WP CSI Pharmaceuticals ETF](https://longbridge.com/en/quote/562050.CN.md)
- [159570.CN - China Universal CNI HK Connect Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159570.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [IHF.US - iShares US Healthcare Providers](https://longbridge.com/en/quote/IHF.US.md)
- [516610.CN - Dacheng CSI All Share Health Care Equipment and Services ETF](https://longbridge.com/en/quote/516610.CN.md)
- [XHS.US - SPDR S&P Health](https://longbridge.com/en/quote/XHS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 基石藥業-B 的肺癌藥物 Sugemalimab 獲得英國第二次批准 | 藥明康德（CStone Pharmaceuticals）已獲得英國批准，將其肺癌藥物 sugemalimab 作為單藥治療用於不可切除的 III 期非小細胞肺癌成人患者。這標誌着該藥物在英國的第二個適應症，得益於 III 期 GEMSTON | [Link](https://longbridge.com/en/news/276549711.md) |
| SRx Health Solutions 披露未能滿足持續上市規則或標準 | SRX Health Solutions 於 2026 年 2 月 18 日收到了紐約證券交易所監管部門的公開警告信，原因是未能遵守上市規則，未獲得額外股份的批准，並在沒有適當股東同意的情況下超過了 20% 的發行閾值。該公司表示，所有優先 | [Link](https://longbridge.com/en/news/276478506.md) |
| 恩賽因集團（NASDAQ:ENSG）董事 Pison Marivic Uychiat 出售 67 股股票 | Ensign Group（納斯達克代碼：ENSG）董事 Pison Marivic Uychiat 以每股 204.92 美元的價格出售了 67 股，總計 13,729.64 美元，導致其持股比例下降 0.47%。出售後，Uychiat 持 | [Link](https://longbridge.com/en/news/276498475.md) |
| 阿爾伯塔投資管理公司降低了其在聯合健康集團公司 $UNH 的股票頭寸 | 阿爾伯塔投資管理公司已大幅減少其在聯合健康集團（NYSE: UNH）中的持股比例，降幅達到 98.8%，目前僅持有 900 股，此前在第三季度出售了 72,500 股。該公司的持股價值為 311,000 美元。其他投資者也在聯合健康集團進行 | [Link](https://longbridge.com/en/news/276427903.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.